PureTech Health to Present at Jefferies 2018 Global Healthcare Conference

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced, clinical-stage biopharmaceutical company, announced today that Joep Muijrers, Ph.D., Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference in New York City on Wednesday, June 6, at 9:30AM EDT.

About PureTech HealthPureTech Health (PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, PureTech Health is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programs, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programs. PureTech’s research and development pipeline has been advanced in collaboration with some of the world’s leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking StatementThis press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180529006292/en/

Investors
PureTech Health
Allison Mead Talbot, +1 617-651-3156
[email protected]
or
U.S. media
Ten Bridge Communications
Tom Donovan, +1 857-559-3397
[email protected]

Source: PureTech Health

You May Also Be Interested In

• Seaport Therapeutics reports positive phase 1 data for GlyphAgo anxiety drug
• Global Heart Hub finds women delay seeking heart care by continuing to put others first
• Bark Inc. (BARK) PT Raised to $19 at Jefferies Following 20:1 Reverse Split